Apnimed Seeks $160M IPO for a Sleep Apnea Pill

Apnimed is asking public investors to back a simple but ambitious proposition: treating obstructive sleep apnea with a pill.

What happened

The late-stage biotechnology company disclosed plans to sell 10 million shares at $14 to $16 each. At the top of the range, the IPO would raise $160 million and value Apnimed at up to $608 million.

The company is developing an oral treatment for obstructive sleep apnea, a condition commonly managed with devices that keep the airway open during sleep.

The offering has not yet priced or closed.

Why it matters

A pill could be easier for some patients to use consistently than device-based treatment. That gives Apnimed a potentially large market if its therapy wins regulatory approval and performs well outside clinical trials.

The proposed IPO would provide capital for late-stage development and preparations for a possible launch. It also exposes public investors to the concentrated risk of a company built mainly around one lead product.

The bigger picture

Biotechnology IPOs are an important test of risk appetite. Apnimed’s offering will show whether public markets are willing to fund late-stage clinical companies before revenue when the commercial opportunity is clear.

For now, both the financing and the medicine remain uncertain: the IPO is only proposed, and the treatment still requires regulatory approval.